Ovarian Cancer

Ovarian Cancer Recent News

Bicycle Therapeutics Stock Falls After Interim Data Of Toxin Conjugates In Ovarian Cancer Trial
Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?
Verastem Shares Are Trading Higher On Encouraging Combo Therapy Data At ESMO Presentation
Deciphera Presents New Data Across Pipeline At ESMO Congress
Corcept Therapeutics' Relacorilant Combo Therapy Shows Clinical Benefit In Ovarian Cancer
Why Are Mersana Therapeutics Shares Trading Lower On Friday?
Mersana Therapeutics Inc (NASDAQ: MRSN) stock is moving lower during the market trading session. Investors are reacting to interim data from the ovarian cancer Phase 1 trial evaluating Upifitamab Rilsodotin (UpRi, previously XMT-1536).
Anixa Biosciences' CAR-T Therapy To Start Human Trial For Ovarian Cancer
Sutro Biopharma's Ovarian Cancer Candidate Fast Tracked In US
IMV's Shares Jump As Ovarian Cancer Candidate Shows Overall Survival Rate Of 44.9%
Sellas Life Sciences Reports Encouraging Immune Response From GPS Combo Trial In Ovarian Cancer
VBL Therapeutics Shares Drop As Pending Clearance Of New Batches Cancer Gene Therapy Hit Recruitment In Ovarian Cancer Trial
The FDA notified VBL Therapeutics Ltd (NASDAQ: VBLT) that clearance of new VB-111 batches for use in the U.S. is currently pending, as review by the Chemistry, Manufacturing, and Controls (CMC) group is still ongoing.
VBL Therapeutics Stock Jumps on Adding PFS as Second Independent Primary Endpoint in Ovarian Cancer Gene Therapy Trial
Verastem's VS-6766/Defactinib Combo Gets Breakthrough Therapy Tag For Ovarian Cancer; BTIG Upgrades Stock
Cancer Focus Fund To Finance Mereo's Ovarian Cancer Study With Etigilimab
Mersana Therapeutics Starts UpRi Dosing In Heavily Pretreated Cohort Of Ovarian Cancer Patients
Celsion's Ovarian Cancer Immunotherapy Shows 41% Improvement In R0 Resection Rates
Vascular Biogenics' Ovarian Cancer Gene Therapy Shows Response Rate Of Over 58%
Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer
Kazia Therapeutics Ltd (NASDAQ: KZIA) has 
Celsion's Ovarian Cancer Immunotherapy Shows 38% Improvement In R0 Resection Rates Versus Control Arm
Vascular Biogenics' Ovarian Cancer Gene Therapy Study To Continue, Recommends An Independent Committee
Celsion Receives Fast Track Tag In US For Ovarian Cancer Immunotherapy
Jury Awards Woman $417 Million On Allegation Johnson & Johnson (NYSE: JNJ) Talcum Powder Gave Her Cancer
Clovis Addresses Some Of The Company's Biggest Controversies